Elevated Erythropoietin in Vitreous of Patients with Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy

Wang, Zhaoyang; Shen, Lijun; Zhao, Keke; Song, Zongming; Qu, Jia

doi:10.1159/000228592

Cited by 8 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study determined that the expression levels of EPO and EPOR were upregulated after RD, reaching a peak at 48 h. 27 Clinical studies have also demonstrated elevated levels of intravitreal EPO after RD. 28 Our previous studies confirmed that EPO in the detached retinas was neutralized by EPOR antagonists, thereby aggravating photoreceptor cell apoptosis after RD (in press). These lines of evidence indicate that the endogenous EPO/EPOR system may protect retinal photoreceptor cells after RD, and suggest that exogenous EPO supplementation could also help to reduce RD-induced damage to retinal photoreceptor cells.…”

Section: Introductionmentioning

confidence: 54%

Safety and efficacy of intravitreal injection of recombinant erythropoietin for protection of photoreceptor cells in a rat model of retinal detachment

Xie

Chen

et al. 2011

Eye

View full text Add to dashboard Cite

Purpose To elucidate the safety and efficacy of exogenous erythropoietin (EPO) for the protection of photoreceptor cells in a rat model of retinal detachment (RD). Methods Recombinant rat EPO (400 ng) was injected into the vitreous cavity of normal rats to observe the eye manifestations. Retinal function was assessed by flash electroretinograms. Histopathological examination of retinal tissue was performed at 14 days and 2 months after injection, respectively. To investigate the inhibitory effect of EPO on photoreceptor cell apoptosis in RD rats, 100, 200, or 400 ng EPO was injected into the vitreous cavity immediately after RD model establishment. Apoptosis of photoreceptor cells was determined at 3 days after injection. Caspase-3 activation was measured by western blot analysis and immunofluorescence, respectively, and the level of Bcl-X L expression was analyzed by western blot. Results Intravitreal injection of EPO 400 ng into normal rats had no significant impact on retinal function, morphology, or structure. Apoptosis of retinal photoreceptor cells apparently increased after RD and was significantly reduced following EPO treatment. The thickness of the outer nuclear layer in the RD þ 400 ng group was significantly thicker than that in other experimental RD groups both at 14 days and at 2 months after RD (Po0.05). Western blot and immunofluorescence analyses showed decreased caspase-3 activation and increased Bcl-X L expression following EPO treatment. Conclusion Intravitreal injection of EPO 400 ng is safe, and EPO may suppress caspase-3 activation and enhance Bcl-X L expression, resulting in inhibition of apoptosis and protection of photoreceptor cells.

show abstract

Section: Introductionmentioning

confidence: 54%

Safety and efficacy of intravitreal injection of recombinant erythropoietin for protection of photoreceptor cells in a rat model of retinal detachment

Xie

Chen

et al. 2011

Eye

View full text Add to dashboard Cite

show abstract

“…The mean level of EPO in the RRD group was significantly higher than that in the idiopathic macular hole control group, and the mean EPO level in PVR was higher than that in RRD, but the difference was not significant. 70 …”

Section: Resultsmentioning

confidence: 99%

Erythropoietin in ophthalmology: A literature review

Aghdam

Sanjari

Falavarjani

2016

Journal of Current Ophthalmology

View full text Add to dashboard Cite

PurposeTo review the current literature on ocular application of erythropoietin (EPO).MethodsA comprehensive search was performed on Pubmed and Scopus databases. All selected articles were reviewed thoroughly by the authors to review current applications of the EPO in ocular diseases.ResultsVarious aspects of administration of EPO for different ischemic, traumatic, vascular, and degenerative disorders have been explained. The articles are generally preclinical with few small studies reporting clinical outcomes.ConclusionEPO has been used for the treatment of different ophthalmic conditions with promising results. Further studies are needed to elaborate the role of EPO in management of ocular diseases.

show abstract

“…It has been shown that the vitreous erythropoietin level is upregulated in eyes with rhegmatogenous retinal detachment 77–79,90. Anterior segment ischemia is a dreaded complication of retinal detachment.…”

Section: Relationship Between Erythropoietin and Retinopathiesmentioning

confidence: 99%

Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration

Rastmanesh

2011

IJGM

View full text Add to dashboard Cite

Repeated blood donors manifest clinical, subclinical, and biochemical signs of iron deficiency anemia, have significantly higher erythropoietin and vascular endothelial growth factor (VEGF) concentrations, and decreased tissue oxygen saturation, oxygenated tissue hemoglobin, and regional cerebral oxygen saturation. Erythropoietin and VEGF are potent retinal angiogenic factors which may initiate and promote the retinal angiogenesis process independently or simultaneously. Increases in circulating levels of erythropoietin and VEGF are proportionate to the levels of hematocrit, hypoxemia, and tissue hypoxia. It is suggested that higher erythropoietin production following iron deficiency anemia-induced chronic hypoxemia/ hypoxia may, hypothetically, enhance the risk of retinal angiogenesis and/or neovascularization, possibly by inducing hypoxia inducible factor-1 alpha, which consequently upregulates genes stimulating angiogenesis, resulting in formation of a new vasculature, possibly by modulation of signal transducer and activator of transcription 3 signaling in the retina. Implications of this hypothesis cover erythropoietin doping, chronic hypoxia, and hypoxemic situations, such as angiogenesis-related cardiac and pulmonary diseases.

show abstract

Elevated Erythropoietin in Vitreous of Patients with Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy

Cited by 8 publications

References 33 publications

Safety and efficacy of intravitreal injection of recombinant erythropoietin for protection of photoreceptor cells in a rat model of retinal detachment

Safety and efficacy of intravitreal injection of recombinant erythropoietin for protection of photoreceptor cells in a rat model of retinal detachment

Erythropoietin in ophthalmology: A literature review

Possibility of enhanced risk of retinal neovascularization in repeated blood donors: blood donation and retinal alteration

Contact Info

Product

Resources

About